查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1825858

2025年聚乙二醇化蛋白質全球市場報告

PEGylated Proteins Global Market Report 2025
出版日期: | 出版商: The Business Research Company | 英文 250 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

預計未來幾年，聚乙二醇化蛋白質市場將快速成長，到2029年將達到27.2億美元，複合年成長率為12.9%。預測期內的成長可歸因於對罕見疾病的投資增加、生物製藥行業的快速發展、精準醫療的調整、來自生物製藥相似藥的競爭加劇以及創新型打入市場策略的採用。預測期內的主要趨勢包括數位健康技術的整合、下一代聚乙二醇化技術、精準醫療的個人化配方、對聯合治療的關注以及向以患者為中心的醫療模式的轉變。

預測的五年成長率為12.9%，較我們先前對該市場的預測略有下降0.8%。這一下降主要源自於美國與其他國家之間關稅的影響。預計關稅壁壘將阻礙美國生物製藥產業的發展，因為這將提高來自瑞士和中國的聚乙二醇化試劑和偶聯生物製藥的成本，減緩新藥的研發速度，並增加生產成本。由於互惠關稅以及貿易摩擦和限制升級對全球經濟和貿易的負面影響，關稅壁壘的影響也將更加廣泛。

文明病的日益流行預計將在未來幾年推動聚乙二醇化蛋白質市場的成長。文明病主要由不良習慣和生活方式選擇（例如不健康的飲食、缺乏運動和吸煙）引起。由於體力活動減少、飲食中富含加工食品以及壓力水平升高等因素，這些疾病正變得越來越普遍。聚乙二醇化蛋白質可用於治療文明病，透過提高治療藥物的療效、持續時間和標靶遞送，治療心血管疾病、糖尿病和某些癌症等疾病。例如，英國政府機構健康改善與差異辦公室於2024年5月報告稱，2022-2023年，英格蘭約有64.0%的18歲及以上成年人被歸類為超重或肥胖，略高於2021-2022年的63.8%。因此，文明病的日益普及正在促進聚乙二醇化蛋白質市場的成長。

目錄

第1章執行摘要

第2章 市場特徵

第3章 市場趨勢與策略

第4章 市場：宏觀經濟情景，包括利率、通膨、地緣政治、貿易戰和關稅，以及新冠疫情和復甦對市場的影響

第5章 全球成長分析與策略分析框架

  • 全球聚乙二醇化蛋白質：PESTEL分析（政治、社會、技術、環境、法律因素、促進因素與限制因素）
  • 最終用途產業分析
  • 全球聚乙二醇化蛋白質市場：成長率分析
  • 全球聚乙二醇化蛋白質市場表現：規模與成長，2019-2024
  • 全球聚乙二醇化蛋白質市場預測：2024-2029年及2034年規模與成長
  • 全球聚乙二醇化蛋白質：總目標市場（TAM）

第6章 市場細分

  • 全球聚乙二醇化蛋白質市場：依產品、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 供應品和服務
  • 聚乙二醇化套件和試劑
  • 單功能線性 PEG
  • 雙功能PEG
  • 其他產品
  • 全球聚乙二醇化蛋白質市場（按蛋白質類型、性能和預測），2019-2024 年、2024-2029 年、2034 年
  • 集落刺激因子
  • 干擾素
  • 促紅血球生成素
  • 重組因子VII
  • 其他類型的蛋白質
  • 全球聚乙二醇化蛋白質市場：按應用、性能和預測，2019-2024 年、2024-2029 年、2034 年
  • 癌症治療
  • 肝炎
  • 慢性腎臟病
  • 血友病
  • 多發性硬化症
  • 胃腸道疾病
  • 其他用途
  • 全球聚乙二醇化蛋白質市場：按最終用戶、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 製藥
  • 生技公司
  • 合約研究組織
  • 學術研究機構
  • 全球聚乙二醇化蛋白質市場：按消耗品和服務細分（按類型）、實際和預測，2019-2024 年、2024-2029 年、2034 年
  • 耗材
  • 服務（合約服務、PEG服務）
  • 全球聚乙二醇化蛋白質市場：聚乙二醇化試劑套件和試劑細分（按類型）、實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 聚乙二醇化套件
  • 試劑
  • 全球聚乙二醇化蛋白質市場：細分：單功能線性聚乙二醇（按類型），實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 用於蛋白質修飾的單功能PEG
  • 全球聚乙二醇化蛋白質市場：依雙功能聚乙二醇類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 用於蛋白質修飾的雙功能PEG
  • 全球聚乙二醇化蛋白質市場：依產品類型細分，實際及預測，2019-2024 年、2024-2029 年、2034 年
  • 共軛
  • 聚乙二醇化藥物和治療學

第7章 區域和國家分析

  • 全球聚乙二醇化蛋白質市場：按地區、績效及預測，2019-2024 年、2024-2029 年、2034 年
  • 全球聚乙二醇化蛋白質市場：依國家、地區、績效及預測（2019-2024 年、2024-2029 年及 2034 年）

第8章 亞太市場

第9章：中國市場

第10章 印度市場

第11章 日本市場

第12章：澳洲市場

第13章 印尼市場

第14章 韓國市場

第15章：西歐市場

第16章英國市場

第17章：德國市場

第18章：法國市場

第19章：義大利市場

第20章：西班牙市場

第21章 東歐市場

第22章：俄羅斯市場

第23章 北美市場

第24章美國市場

第25章：加拿大市場

第26章 南美洲市場

第27章：巴西市場

第28章 中東市場

第29章：非洲市場

第30章：競爭格局與公司概況

  • 聚乙二醇化蛋白質市場：競爭格局
  • 聚乙二醇化蛋白質市場：公司簡介
    • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
    • Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

第31章：其他領先和創新企業

  • Gilead Sciences Inc.
  • Novo Nordisk A/S
  • Evonik Industries AG
  • Viatris Inc.
  • Regeneron Pharmaceuticals Inc.
  • Biogen Inc.
  • Vertex Pharmaceuticals Incorporated
  • Lonza Group Ltd.
  • Jazz Pharmaceuticals plc
  • Ipsen Pharma
  • Kyowa Kirin Co. Ltd.
  • WuXi Biologics
  • BioMarin Pharmaceutical Inc.
  • Ligand Pharmaceuticals Incorporated
  • Zydus Cadila

第 32 章全球市場競爭基準化分析與儀表板

第33章 重大併購

第34章近期市場趨勢

第 35 章：高潛力市場國家、細分市場與策略

  • 2029 年聚乙二醇化蛋白質市場：提供新機會的國家
  • 2029 年聚乙二醇化蛋白質市場：細分市場帶來新機會
  • 2029 年聚乙二醇化蛋白質市場：成長策略
    • 基於市場趨勢的策略
    • 競爭對手策略

第36章 附錄

簡介目錄
Product Code: r30913u

PEGylated proteins are therapeutic proteins covalently bonded to polyethylene glycol (PEG), a process aimed at enhancing their pharmacokinetic properties and reducing immunogenicity, thus improving their therapeutic efficacy. These modified proteins find application in various medical fields, including drug delivery, diagnostics, and targeted therapy, offering prolonged action and potentially improving patient outcomes.

The primary products within the PEGylated proteins market include consumables and services, pegylation kits and reagents, monofunctional linear PEGs, bifunctional PEGs, and others. Consumables and services constitute a broad category encompassing products and services vital for PEGylated protein research and development, including kits, reagents, and various support services. The proteins themselves cover a range of types such as colony-stimulating factors, interferons, erythropoietin, recombinant factor VII, and others, serving diverse applications including cancer treatment, hepatitis, chronic kidney diseases, hemophilia, multiple sclerosis, gastrointestinal disorders, and more. End users of these products and services include pharmaceutical companies, biotechnology firms, contract research organizations, and academic research institutes.

Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.

The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.

The PEGylated proteins market research report is one of a series of new reports from The Business Research Company that provides PEGylated proteins market statistics, including the PEGylated proteins industry global market size, regional shares, competitors with the PEGylated proteins market share, detailed PEGylated proteins market segments, market trends, and opportunities, and any further data you may need to thrive in the PEGylated proteins industry. These PEGylated proteins market research reports deliver a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The pegylated proteins market size has grown rapidly in recent years. It will grow from $1.47 billion in 2024 to $1.67 billion in 2025 at a compound annual growth rate (CAGR) of 13.8%. The growth in the historic period can be attributed to improved therapeutic efficacy, a growing aging population, demand for long-acting formulations, enhanced drug safety profiles, and expanding applications including targeted drug delivery systems.

The pegylated proteins market size is expected to see rapid growth in the next few years. It will grow to $2.72 billion in 2029 at a compound annual growth rate (CAGR) of 12.9%. The growth in the forecast period can be attributed to increasing investment in rare diseases, rapid growth of the biopharmaceutical industry, precision medicine tailoring, increasing competition from biosimilar versions of biologic drugs, and adoption of innovative market access strategies. Major trends in the forecast period include the integration of digital health technologies, next-generation pegylation technologies, customized formulations for precision medicine, a focus on combination therapies, and a shift towards patient-centric healthcare models.

The forecast of 12.9% growth over the next five years reflects a modest reduction of 0.8% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Tariff barriers are expected to hamper the U.S. biopharma sector by increasing the cost of PEGylation reagents and conjugated biologic drugs sourced from Switzerland and China, thereby delaying novel drug formulations and elevating manufacturing costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.

The growing prevalence of lifestyle diseases is expected to drive the growth of the PEGylated proteins market in the coming years. Lifestyle diseases are health conditions primarily caused by poor habits and lifestyle choices, such as an unhealthy diet, lack of physical activity, and smoking. These diseases are becoming more common due to factors like reduced physical activity, diets rich in processed foods, and heightened stress levels. PEGylated proteins are used in the treatment of lifestyle diseases by improving the effectiveness, duration, and targeted delivery of therapeutic agents for conditions like cardiovascular diseases, diabetes, and some cancers. For example, in May 2024, the Office for Health Improvement and Disparities, a UK-based government agency, reported that in 2022-2023, approximately 64.0% of adults aged 18 and over in England were classified as overweight or obese, a slight increase from 63.8% in 2021-2022. As a result, the rising prevalence of lifestyle diseases is contributing to the growth of the PEGylated proteins market.

Key players in the PEGylated proteins market are focusing on the development of innovative products such as PEGylation reagents to maintain a competitive edge. PEGylation reagents are chemical compounds that attach polyethylene glycol (PEG) chains to biomolecules, modifying their properties for various biomedical applications. For instance, Creative Enzymes, a US-based supplier of food additives and enzymes, introduced DSPE-PEG-Maleimide in May 2023 for targeted drug delivery. DSPE-PEG-Maleimide is a linear heterobifunctional PEGylation reagent containing DSPE phospholipids and maleimide, serving as a valuable self-assembly reagent for preparing PEGylated liposomes or micelles and providing thiol or cysteine reactive maleimide groups, commonly used in targeted drug delivery.

In February 2022, Merck KGaA, a pharmaceutical company based in Germany, acquired Exelead Inc. for $793 million to bolster its presence in the growing market for mRNA therapeutics. Exelead Inc., a US-based biopharmaceutical company specializing in GMP-certified PEGylation services for use in manufacturing process development, is expected to enhance Merck KGaA's capabilities in this sector.

Major companies operating in the PEGylated proteins market are Merck & Co. Inc., Bayer AG, Bristol Myers Squibb Company, AstraZeneca PLC, Roche Holding AG, Gilead Sciences Inc., Novo Nordisk A/S, Evonik Industries AG, Viatris Inc., Regeneron Pharmaceuticals Inc., Biogen Inc., Vertex Pharmaceuticals Incorporated, Lonza Group Ltd., Jazz Pharmaceuticals plc, Ipsen Pharma, Kyowa Kirin Co. Ltd., WuXi Biologics, BioMarin Pharmaceutical Inc., Ligand Pharmaceuticals Incorporated, Zydus Cadila, Enzon Pharmaceuticals Inc.

North America was the largest region in the PEGylated Proteins market in 2024. The regions covered in the PEGylated proteins market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the PEGylated proteins market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The PEGylated proteins market consists of revenues earned by entities by providing services such as analytical services and contract manufacturing services for PEGylated protein. The market value includes the value of related goods sold by the service provider or included within the service offering. The PEGylated proteins market also includes sales of PEGylated enzymes, PEGylated antibodies, and PEGylated hormones. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

PEGylated Proteins Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on pegylated proteins market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for pegylated proteins ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pegylated proteins market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Product: Consumable And Services; PEGylation Kits And Reagents; Monofunctional Linear PEGs; Bifunctional PEGs; Services; Other Products
  • 2) By Protein Type: Colony Stimulating Factors; Interferons; Erythropoietin; Recombinant Factor VII; Other Protein Types
  • 3) By Application: Cancer Treatment; Hepatitis; Chronic Kidney Diseases; Hemophilia; Multiple Sclerosis; Gastrointestinal Disorders; Other Applications
  • 4) By End User: Pharmaceuticals; Biotechnology Companies; Contract Research Organizations; Academic Research Institutes
  • Subsegments:
  • 1) By Consumable And Services: Consumables; Services (Contract Services, PEGylation Services)
  • 2) By PEGylation Kits And Reagents: PEGylation Kits; Reagents
  • 3) By Monofunctional Linear PEGs: Monofunctional PEGs For Protein Modification
  • 4) By Bifunctional PEGs: Bifunctional PEGs For Protein Modification
  • 5) By Other Products: Conjugates; PEGylated Drugs And Therapeutics
  • Companies Mentioned: Merck & Co. Inc.; Bayer AG; Bristol Myers Squibb Company; AstraZeneca PLC; Roche Holding AG; Gilead Sciences Inc.; Novo Nordisk A/S; Evonik Industries AG; Viatris Inc.; Regeneron Pharmaceuticals Inc.; Biogen Inc.; Vertex Pharmaceuticals Incorporated; Lonza Group Ltd.; Jazz Pharmaceuticals plc; Ipsen Pharma; Kyowa Kirin Co. Ltd.; WuXi Biologics; BioMarin Pharmaceutical Inc.; Ligand Pharmaceuticals Incorporated; Zydus Cadila; Enzon Pharmaceuticals Inc.
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time Series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. PEGylated Proteins Market Characteristics

3. PEGylated Proteins Market Trends And Strategies

4. PEGylated Proteins Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

  • 4.1. Supply Chain Impact from Tariff War & Trade Protectionism

5. Global PEGylated Proteins Growth Analysis And Strategic Analysis Framework

  • 5.1. Global PEGylated Proteins PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global PEGylated Proteins Market Growth Rate Analysis
  • 5.4. Global PEGylated Proteins Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global PEGylated Proteins Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global PEGylated Proteins Total Addressable Market (TAM)

6. PEGylated Proteins Market Segmentation

  • 6.1. Global PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Consumable And Services
  • PEGylation Kits And Reagents
  • Monofunctional Linear PEGs
  • Bifunctional PEGs
  • Other Products
  • 6.2. Global PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Colony Stimulating Factors
  • Interferons
  • Erythropoietin
  • Recombinant Factor VII
  • Other Protein Types
  • 6.3. Global PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Cancer Treatment
  • Hepatitis
  • Chronic Kidney Diseases
  • Hemophilia
  • Multiple Sclerosis
  • Gastrointestinal Disorders
  • Other Applications
  • 6.4. Global PEGylated Proteins Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Pharmaceuticals
  • Biotechnology Companies
  • Contract Research Organizations
  • Academic Research Institutes
  • 6.5. Global PEGylated Proteins Market, Sub-Segmentation Of Consumable And Services, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Consumables
  • Services (Contract Services, PEGylation Services)
  • 6.6. Global PEGylated Proteins Market, Sub-Segmentation Of PEGylation Kits And Reagents, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • PEGylation Kits
  • Reagents
  • 6.7. Global PEGylated Proteins Market, Sub-Segmentation Of Monofunctional Linear PEGs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Monofunctional PEGs For Protein Modification
  • 6.8. Global PEGylated Proteins Market, Sub-Segmentation Of Bifunctional PEGs, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Bifunctional PEGs For Protein Modification
  • 6.9. Global PEGylated Proteins Market, Sub-Segmentation Of Other Products, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Conjugates
  • PEGylated Drugs And Therapeutics

7. PEGylated Proteins Market Regional And Country Analysis

  • 7.1. Global PEGylated Proteins Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global PEGylated Proteins Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific PEGylated Proteins Market

  • 8.1. Asia-Pacific PEGylated Proteins Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China PEGylated Proteins Market

  • 9.1. China PEGylated Proteins Market Overview
  • 9.2. China PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India PEGylated Proteins Market

  • 10.1. India PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan PEGylated Proteins Market

  • 11.1. Japan PEGylated Proteins Market Overview
  • 11.2. Japan PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia PEGylated Proteins Market

  • 12.1. Australia PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia PEGylated Proteins Market

  • 13.1. Indonesia PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea PEGylated Proteins Market

  • 14.1. South Korea PEGylated Proteins Market Overview
  • 14.2. South Korea PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe PEGylated Proteins Market

  • 15.1. Western Europe PEGylated Proteins Market Overview
  • 15.2. Western Europe PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK PEGylated Proteins Market

  • 16.1. UK PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany PEGylated Proteins Market

  • 17.1. Germany PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France PEGylated Proteins Market

  • 18.1. France PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy PEGylated Proteins Market

  • 19.1. Italy PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain PEGylated Proteins Market

  • 20.1. Spain PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe PEGylated Proteins Market

  • 21.1. Eastern Europe PEGylated Proteins Market Overview
  • 21.2. Eastern Europe PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia PEGylated Proteins Market

  • 22.1. Russia PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America PEGylated Proteins Market

  • 23.1. North America PEGylated Proteins Market Overview
  • 23.2. North America PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA PEGylated Proteins Market

  • 24.1. USA PEGylated Proteins Market Overview
  • 24.2. USA PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada PEGylated Proteins Market

  • 25.1. Canada PEGylated Proteins Market Overview
  • 25.2. Canada PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America PEGylated Proteins Market

  • 26.1. South America PEGylated Proteins Market Overview
  • 26.2. South America PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil PEGylated Proteins Market

  • 27.1. Brazil PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East PEGylated Proteins Market

  • 28.1. Middle East PEGylated Proteins Market Overview
  • 28.2. Middle East PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa PEGylated Proteins Market

  • 29.1. Africa PEGylated Proteins Market Overview
  • 29.2. Africa PEGylated Proteins Market, Segmentation By Product, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa PEGylated Proteins Market, Segmentation By Protein Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa PEGylated Proteins Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. PEGylated Proteins Market Competitive Landscape And Company Profiles

  • 30.1. PEGylated Proteins Market Competitive Landscape
  • 30.2. PEGylated Proteins Market Company Profiles
    • 30.2.1. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. Bayer AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Bristol Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. AstraZeneca PLC Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. Roche Holding AG Overview, Products and Services, Strategy and Financial Analysis

31. PEGylated Proteins Market Other Major And Innovative Companies

  • 31.1. Gilead Sciences Inc.
  • 31.2. Novo Nordisk A/S
  • 31.3. Evonik Industries AG
  • 31.4. Viatris Inc.
  • 31.5. Regeneron Pharmaceuticals Inc.
  • 31.6. Biogen Inc.
  • 31.7. Vertex Pharmaceuticals Incorporated
  • 31.8. Lonza Group Ltd.
  • 31.9. Jazz Pharmaceuticals plc
  • 31.10. Ipsen Pharma
  • 31.11. Kyowa Kirin Co. Ltd.
  • 31.12. WuXi Biologics
  • 31.13. BioMarin Pharmaceutical Inc.
  • 31.14. Ligand Pharmaceuticals Incorporated
  • 31.15. Zydus Cadila

32. Global PEGylated Proteins Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The PEGylated Proteins Market

34. Recent Developments In The PEGylated Proteins Market

35. PEGylated Proteins Market High Potential Countries, Segments and Strategies

  • 35.1 PEGylated Proteins Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 PEGylated Proteins Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 PEGylated Proteins Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer